[Zoster disease after Shingrix vaccination]

Area of Science:

• Vaccinology
• Immunology
• Dermatology

Background:

• Shingrix is a recombinant adjuvant subunit vaccine.
• It is approved in Germany for preventing zoster (shingles) and postherpetic neuralgia in adults aged 60 years and older.

Purpose of the Study:

• To inform healthcare providers about Shingrix vaccine indications and potential adverse events.
• To emphasize the importance of considering zoster disease in cases of bullous skin lesions post-vaccination.

Main Methods:

• Review of vaccine approval information and clinical guidelines.
• Clinical observation and reporting of adverse events.

Main Results:

• Shingrix is indicated for zoster prevention in adults aged ≥60 years.
• Bullous skin lesions after Shingrix vaccination may indicate zoster disease.

Conclusions:

• Healthcare providers should be vigilant for zoster manifestations in vaccinated individuals presenting with specific skin lesions.
• Reporting unexpected side effects to the Drug Commission of the German Medical Association is crucial for vaccine safety monitoring.